glp 1 and kidney cancer Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus Chronic Disease: A Narrative Review of the Key Evidence with Practical Considerations | Diabetes Therapy Potential kidney-protective and other effects

Tong C, Liang H, Liu X, Yuan B, Xue B, Tong Z, et al

Research demonstrates that: Men taking semaglutide showed higher rates of testosterone deficiency (3.83%) compared to those not taking the medication (1.7%) The medication influences GLP-1 hormone levels, which affects various metabolic processes Hormonal changes may be more pronounced during initial weight loss periods [12] Important Considerations for Hormone Function: Weight loss achieved through Wegovy may lead to positive hormonal adjustments

While the Bridge is an important milestone, it should also be a catalyst for creating a permanent pathway to comprehensive obesity care within Medicare and across private insurance as well." Following the announcement, Novo Nordisk says it is working with CMS, healthcare professionals, pharmacists and patient advocacy organizations to support the program's rollout

The trial did not include a 2.5 mg maintenance arm because 2.5 mg is designed as a four-week titration step, not a therapeutic target

PMCID: PMC9385793